UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of October 2025

August 7, 2025

Commission File Number: 001-36622

PROQR THERAPEUTICS N.V.

Zernikedreef 9

2333 CK Leiden

The Netherlands

Tel: +31 88 166 7000

(Address, Including ~~ZIP~~Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

Including Area Code, of Registrant’s Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 206-~~F ⌧ Form 40~~K in paper as permitted by Regulation S-~~F ◻~~T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

~~Indicate~~On byOctober 20, ~~check~~2025, ProQR ~~mark~~Therapeutics ifN.V. ~~the~~(“ProQR”) ~~registrant~~issued isa ~~submitting~~press ~~the~~release ~~Form 6~~titled “ProQR Receives CTA Authorization for AX-K0810 inand ~~paper~~Announces Virtual asInvestor ~~permitted~~and byAnalyst ~~Regulation~~Event ~~S-T~~on ~~Rule~~November ~~101(b)(~~3, 2025.” A copy of the press release is attached hereto as Exhibit 99.1~~): ◻~~ and is incorporated herein by reference.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

Furnished as Exhibit 99.1 to this Report on Form 6-K are the unaudited financial statements of ProQR Therapeutics N.V. (the “Company”) for the three and six-month periods ended June 30, 2025, and furnished as Exhibit 99.2 to this Report on Form 6-K is a press release of ProQR Therapeutics N.V. dated August 7, 2025, announcing the Company’s results for the three and six-month periods ended June 30, 2025.

On August 7, 2025, the Company issued a press release titled, “ProQR Announces Second Quarter 2025 Operating and Financial Results,” announcing the Company’s results for the three and six-month periods ended June 30, 2025 and providing a business update. A copy of this press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

ProQR hereby incorporates by reference the information contained herein into ProQR’s registration statements on Form F-3 (File No. 333-282419, File No. 333-270943, File No. 333-263166 and File No. 333-285767).

INDEX TO EXHIBITS

Number		Description

99.1		Unaudited financial statements of ProQR Therapeutics N.V. for the three and six-month periods ended June 30, 2025.

99.2		Press Release of ProQR Therapeutics N.V. dated August 7, 2025, announcing the Company’s results for the three and six-month periods ended June 30, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PROQR THERAPEUTICS N.V.

Date: October 20, 2025	By:	/s/ Dennis Hom
		Dennis Hom
		Chief Financial Officer

INDEX TO EXHIBITS


Number		Description
	PROQR THERAPEUTICS N.V.
99.1		Press Release of ProQR Therapeutics N.V. dated October 20, 2025.


Date: August 7, 2025	By:	/s/ Dennis Hom
		Dennis Hom
		Chief Financial Officer

Filing Compare · ProQR Therapeutics N.V.